Textual content signal exhibiting Trade Information. Enterprise picture textual content delivering information to most of the people or a goal public | Picture Credit score: © Artur – inventory.adobe.com
An acquisition of the contract growth and manufacturing group (CDMO) Synerlab Group, mixed with the securing of seven manufacturing websites in Europe previously belonging to Recipharm, resulted on April 15, 2025 within the announcement of the launch of a brand new, mid-sized CDMO, Meribel Pharma Options, headquartered in the UK (1).
In keeping with a press launch issued by the brand new firm, the Meribel moniker comes from the mountain vary of the identical identify within the Alps, positioned within the Three Valleys area of France, which the corporate mentioned signifies its ten manufacturing websites and three drug growth providers websites in France, Spain, and Sweden (1).
At launch, the Meribel Pharma Options management group consists of CEO Bruce Vielle, previously the president and CEO of Synerlab, and COO Steve Leonard, beforehand company vice chairman of International Operations & Provide Chain at Integra Life Sciences (1).
“There’s a hole available in the market for a niche-player, mid-sized CDMO that’s targeted, agile, and devoted to fixing complicated challenges, and we’re nicely positioned to meet this unmet want,” Vielle mentioned in a press launch from Meribel (1). “We’ve invested closely within the newest applied sciences and expanded our capability to fulfill the evolving wants of our clients. As a unified group, our foundations are constructed on high quality and reliability. We carry collectively better sources, deeper experience, and enhanced agility, enabling us to fulfill our clients’ necessities higher than ever earlier than.”
Within the press launch, the corporate mentioned it has established facilities of excellence in drug growth, lyophilization, preservative-free multidose applied sciences, and versatile stick-pack and sachet manufacturing, meant to assist each human and veterinary well being merchandise whereas working underneath stringent world regulatory certifications (1). The technical experience Meribel mentioned its group is ready to ship is constructed on expertise in such areas as oral stable dose manufacturing, semi-solid dosage formulations, and sterile drug merchandise.
“We’re deeply dedicated to delivering the very best high quality in the whole lot we do,” Vielle mentioned. “Our regulatory and high quality specialists work with our purchasers to assist guarantee their merchandise exceed probably the most stringent requirements. With licensed websites and a shared concentrate on steady enchancment, we’re set as much as ship distinctive outcomes.”
As a part of its protection of the Drug, Chemical, and Related Applied sciences Affiliation (DCAT) Week 2025, Pharmaceutical Know-how® interviewed Simon Wright, vice-president of Enterprise Improvement for Almac Pharma Providers, about recognizing the worth of CDMOs (2).
“We’re actually seeing a need for extra of a strategic partnership versus perhaps extra of that conventional transaction relationship [from sponsor companies],” Wright mentioned within the interview (2). “I really consider that the evolution of sponsor CDMO relationships displays how pharmaceutical firms acknowledge the worth of CDMOs inside their general community and ecosystem. I believe that probably the most strategic relationships at the moment are characterised by strategic partnership strategy the place firms leverage specialist experience and belief the CDMOs to imagine better duty and ship substantial worth.”
Click on right here for the total video interview with Wright.
Financially, Meribel Pharma Options mentioned it’s backed by Blue Wolf Capital Companions LLC, a middle-market non-public fairness agency that makes a speciality of the healthcare and industrial sectors (1).
References
1. Meribel Pharma Options. Meribel Pharma Options Launches with Massive Ambitions to Elevate Pharma Providers to New Heights. Press Launch. April 15, 2025.
2. Thomas, F. DCAT Week 2025: Recognizing the Worth of CDMOs. PharmTech.com, March 18, 2025.
